Interactions of ceftobiprole with β-lactamases from molecular classes A to D

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3089-3095

  Queenan, Anne Marie ^a   Shang, Wenchi ^a   Kania, Malgosia ^b   Page, Malcolm G P ^b   Bush, Karen ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE TEM 1; CEFALORIDINE; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; PENICILLIN G;

ARTICLE; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; DRUG STABILITY; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENZYME SUBSTRATE COMPLEX; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMASES; CEFTAZIDIME; CEPHALOSPORINS; HYDROLYSIS; KINETICS; MICROBIAL SENSITIVITY TESTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 35948961490     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00218-07     Document Type: Article

References (41)

1. Alvarez, M., J. H. Tran, N. Chow, and G. A. Jacoby. 2004. Epidemiology of conjugative plasmid-mediated AmpC β-lactamases in the United States. Antimicrob. Agents Chemother. 48:533-537.
2. Ambler, R. P. 1975. The amino acid sequence of Staphylococcus aureus penicillinase. Biochem. J. 151:197-218.
3. Bogdanovich, T., L. M. Ednie, S. Shapiro, and P. C. Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219.
4. Bradford, P. A. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951.
5. Bradford, P. A., S. Bratu, C. Urban, M. Visalli, N. Mariano, D. Landman, J. J. Rahal, S. Brooks, S. Cebular, and J. Quale. 2004. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin. Infect. Dis. 39:55-60.
6. Bratu, S., D. Landman, R. Haag, R. Recco, A. Eramo, M. Alam, and J. Quale. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165:1430-1435.
7. Bush, K., J. S. Freudenberger, and R. B. Sykes. 1982. Interaction of aztreonam and related monobactams with β-lactamases from gram-negative bacteria. Antimicrob. Agents Chemother. 22:414-420.
8. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
9. Bush, K., and R. B. Sykes. 1986. Methodology for the study of β-lactamases. Antimicrob. Agents Chemother. 30:6-10.
10. Bush, K., S. K. Tanaka, D. P. Bonner, and R. B. Sykes. 1985. Resistance caused by decreased penetration of β-lactam antibiotics into Enterobacter cloacae. Antimicrob. Agents Chemother. 27:555-560.
11. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099-3108.
12. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; approved standard M100-S16, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A7, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Davies, T. A., W. Shang, and K. Bush. 2006. Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob. Agents Chemother. 50:2530-2532.
15. Denis, O., A. Deplano, C. Nonhoff, M. Hallin, R. De Ryck, R. Vanhoof, R. De Mendonca, and M. J. Struelens. 2006. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob. Agents Chemother. 50:2680-2685.
16. Hanson, N. D., and C. C. Sanders. 1999. Regulation of inducible AmpC β-lactamase expression among Enterobacteriaceae. Curr. Pharm. Design 5:881-894.
17. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
18. Issa, N. C., M. S. Rouse, K. E. Piper, W. R. Wilson, J. M. Steckelberg, and R. Patel. 2004. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 48:73-75.
19. Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenbach. 2002. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50:915-932.
20. Leatherbarrow, R. 1989. GraFit. In U. K. Staines (ed.), Data analysis and graphics program for the IBM PC. Erithacus Software, Surrey, United Kingdom.
21. Lolans, K., A. M. Queenan, K. Bush, A. Sahud, and J. P. Quinn. 2005. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-β-lactamase (VIM-2) in the United States. Antimicrob. Agents Chemother. 49:3538-3540.
22. Lovering, A., F. Danel, M. G. P. Page, and N. J. Strynadka. 2006. Abstr. 16th Eur. Congr. Clin. Microbiol. Infect. Dis., abstr. p1586, Nice, France.
23. Lowy, F. D. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Investig. 111:1265-1273.
24. Olsen, J. E., H. Christensen, and F. M. Aarestrup. 2006. Diversity and evolution of blaZ from Staphylococcus aureus and coagulase-negative staphylococci. J. Antimicrob. Chemother. 57:450-460.
25. Page, M. G. 1993. The kinetics of non-stoichiometric bursts of β-lactam hydrolysis catalysed by class C β-lactamases. Biochem. J. 295:295-304.
26. Page, M. G. P., P. Caspers, and M. Kania. 2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1157.
27. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
28. Poirel, L., M. Gniadkowski, and P. Nordmann. 2002. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3. J. Antimicrob. Chemother. 50:1031-1034.
29. Queenan, A. M., W. Shang, P. Schreckenberger, K. Lolans, K. Bush, and J. Quinn. 2006. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing β-lactamases. Antimicrob. Agents Chemother. 50:3485-3487.
30. Rouse, M. S., M. M. Hein, P. Anguita-Alonso, J. M. Steckelberg, and R. Patel. 2006. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn. Microbiol. Infect. Dis. 55:333-336.
31. Sanders, C. C. 1984. Inducible β-lactamases and non-hydrolytic resistance mechanisms. J. Antimicrob. Chemother. 13:1-3.
32. Seetulsingh, P. S., J. F. Tomayko, P. E. Coudron, S. M. Markowitz, C. Skinner, K. V. Singh, and B. E. Murray. 1996. Chromosomal DNA restriction endonuclease digestion patterns of β-lactamase-producing Enterococcus faecalis isolates collected from a single hospital over a 7-year period. J. Clin. Microbiol. 34:1892-1896.
33. Soge, O. O., A. M. Queenan, K. K. Ojo, B. A. Adeniyi, and M. C. Roberts. 2006. CTX-M-15 extended-spectrum β-lactamase from Nigerian Klebsiella pneumoniae. J. Antimicrob. Chemother. 57:24-30.
34. Streit, J. M., R. N. Jones, H. S. Sader, and T. R. Fritsche. 2004. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int. J. Antimicrob. Agents 24:111-118.
35. Sykes, R. B., D. P. Bonner, K. Bush, and N. H. Georgopapadakou. 1982. Aztreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob. Agents Chemother. 21:85-92.
36. Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18:306-325.
37. Walther-Rasmussen, J., and N. Hoiby. 2006. OXA-type carbapenemases. J. Antimicrob. Chemother. 57:373-383.
38. Wong-Beringer, A., J. Hindler, M. Loeloff, A. M. Queenan, N. Lee, D. A. Pegues, J. P. Quinn, and K. Bush. 2002. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin. Infect. Dis. 34:135-146.
39. Yigit, H., A. M. Queenan, J. K. Rasheed, J. W. Biddle, A. Domenech-Sanchez, S. Alberti, K. Bush, and F. C. Tenover. 2003. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob. Agents Chemother. 47:3881-3889.
40. Zbinden, R., V. Punter, and A. von Graevenitz. 2002. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters. Antimicrob. Agents Chemother. 46:871-874.
41. Zygmunt, D. J., C. W. Stratton, and D. S. Kernodle. 1992. Characterization of four β-lactamases produced by Staphylococcus aureus. Antimicrob. Agents Chemother. 36:440-445.